CalciMedica reports Q3 net loss $5.6M, completes $10.2M offering; cash runway into H1 2026

CalciMedica, Inc.

2024-Q3 EPS reported -$0.88

Q3 2024 net loss $5.6M ($0.50/sh); total loss from operations $5.7M.
Cash $14.6M at Sep 30; pro forma after Oct offering ~$23.7M, funds ops into H1 2026.
Completed Nov 1 public offering: 2.72M shares at $3.75, gross proceeds $10.2M.
Phase 2b CARPO: win ratio 1.64 (p=0.0372) for high-dose Auxora vs placebo; 100% relative risk reduction in new-onset severe respiratory failure.
Expects Phase 3 start in 2025; topline data from KOURAGE (AKI) and CRSPA (AIPT) trials in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.